News

Sanofi plans to axe 2000 jobs
Enlarge image

BusinessFrance

Sanofi plans to axe 2000 jobs

06.07.2012 - The French pharma giant is preparing for a major overhaul of activities in its home market.

Exact numbers are not yet final, but French unions already fear the worst. An estimate of 2,000 jobs lost is “probably close to reality,” said Thierry Bodin, a representative of the CGT union after a meeting with managers today. Europe’s third-biggest drugmaker wants to regroup its research in the Paris region and around Lyon, he said. This might be the end for research in Toulouse, where the blockbuster Plavix blood thinner was developed, and Montpellier. The company also plans to eliminate support functions and cut jobs at its Pasteur vaccine division, Bodin said.

Reuters reports, that Chief Executive Chris Viehbacher told employees that the unspecified number of job cuts, at its Toulouse and Montpellier sites, would be achieved through voluntary redundancies, early retirement and internal mobility. Manufacturing sites in France would not be affected by the project. Jean-Marc Podvin, a spokesman for Sanofi, said in a telephone interview with Bloomberg Businessweek, that no job cut figures were given and all options remain open for Toulouse. Montpellier could become a centre focused on clinical development, he added.

The company’s CEO Viehbacher began to restructure Sanofi in 2009 reducing headcount, closing plants and dropping the least promising projects. As part of a strategic shift, the French drugmaker is aiming at reducing internal research and having other actors, such as small biotechs, academic research to find new molecules and vaccines.

In its course to concentrate on its core competencies, Sanofi has decided to divest its 19.3% stake in the Yves Rocher Group, which operates in a variety of sectors, including cosmetics, home care products and clothing. The Rocher family which already controls most of the company will buy the shares and raise its stake to more than 95%.

http://www.european-biotechnology-news.com/news/news/2012-03/sanofi-plans-to-axe-2000-jobs.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015